Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.
Highlights this week included:
EU: Proposed EU Customs Regulation may not dispel fear of wrongful drug seizures (IP Watch)
Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.
General
WIPO SCP16: Joint proposal of the African Group and the Development Agenda Group on a work program on Patents and Health (Knowledge Ecology International)
Rogue pharmacies slide under Google radar (IP Osgoode)
Australia slips further out-of-step on pharmaceutical extensions (Patentology)
EU: Proposed EU Customs Regulation may not dispel fear of wrongful drug seizures (IP Watch)
EU: Karl De Gucht writes Andris Piebalgs on topic of European Union IPR demands on India and other developing countries (Knowledge Ecology International)
India: Patents do not hinder access? – response to OPPI vice chairman’s interview with the Financial Express (Spicy IP)
Japan: IP High Court guidance on availability of patent term extension for new forms of previously approved medicine (The SPC Blog)
Japan – IP High Court offers guidance on patent term extension for combination of known drugs (The SPC Blog)
Switzerland – The Swiss Federal Supreme Court approves new dosage regime as patentable subject matter in Swiss Type Claims under the EPC 1973 – Merck (Kluwer Patent Blog)
US: FDA posts on its website, then removes, draft guidance that would restrict research use only, investigational use only status (FDA Law Blog)
Products
Actos (Pioglitazone) – US: Takeda files patent infringement complaint against Macleods Pharmaceuticals in response to Para IV certification (Patent Docs)
Amrix (Cyclobenzaprine) – US: Post-trial TRO does not require showing of likelihood of success on the merits: In re: Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation (Docket Report)
Antara (Fenofibrate) – US: Lupin files patent infringement complaints in ED Penn. and WD Penn. against Mylan, Ethypharm in response to Para IV certification (Patent Docs)
AzaSite (Azithromycin) – US: InSite Vision announces joint patent infringement lawsuit with Merck against Sandoz in response to ANDA filing (GenericsWeb)
Carbatrol (Carbamazepine) – US: FDA is sued over generic Carbatrol; lawsuit challenges FDA decisions on pre-MMA 180-day exclusivity (FDA Law Blog)
Drospirenone – Italy: Court of Turin says ‘no’ to the patentability of intermediates (Kluwer Patent Blog)
Frontline Combo – France: Tribunal de Grande Instance: Revocation action inadmissible for lack of personal interest: Omnipharm Limited v. Merial (EPLAW)
Neurontin (Gabapentin) – US: Teva settles Pfizer case on generic epilepsy drug with undisclosed terms (GenericsWeb)
Noxafil (Posaconazole) – US: Schering files patent infringement complaint against Sandoz in response to Para IV certification (Patent Docs)
Patanol (Olopatadine) – US: Alcon wins Patanol patent infringement lawsuit against Apotex (GenericsWeb)
Prandin (Repaglinide) – US: Obama Administration urges Supreme Court to grant certiorari in case on Orange Book patent use codes: Caraco Pharm. Labs. v. Novo Nordisk (Orange Book Blog)
Silenor (Doxepin) – US: Somaxon files patent infringement lawsuit against Par Pharmaceuticals over bid to market generic Silenor (GenericsWeb)
Strattera (Atomoxetine) – US: Eli Lilly files patent infringement complaint against Zydus in response to Para IV certification (Patent Docs)
Zemplar (Paricalcitol) – US: Abbott Lab’s files patent infringement complaint against Sandoz in response to Para IV certification (Patent Docs)
Ziana (Clindamycin, Tretinoin) – US: Medicis files patent infringement complaint against Actavis over ANDA filing (Patent Docs)